Pharmaust Limited (ECQ0) Price & Analysis

Compare

3 Followers

ECQ0 Stock Chart & Stats

Day’s Range― - ―

52-Week Range€0.04 - €0.14

Previous CloseN/A

Volume0.00

Average Volume (3M)543.00

Market Cap

€42.53M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)1.39M

Price to Earnings (P/E)―

Beta1.31

Next Earnings

Aug 29, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding492,305,760

10 Day Avg. Volume0

30 Day Avg. Volume543

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€0.25

Price Target Upside212.50% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Pharmaust Limited News

PremiumCompany Announcements

Neurizon Therapeutics Issues Unquoted Equity Securities

4d ago

PremiumCompany Announcements

Neurizon Therapeutics Unveils Liquid Formulation of NUZ-001 for ALS

5d ago

PremiumCompany Announcements

Neurizon Therapeutics’ NUZ-001 Shows Promising Blood-Brain Barrier Penetration

11d ago

PremiumCompany Announcements

Neurizon Therapeutics to Release Shares from Escrow

14d ago

PremiumCompany Announcements

Neurizon Therapeutics Relocates Headquarters to Enhance Operations

29d ago

PremiumCompany Announcements

Neurizon Therapeutics to Present Promising ALS Treatment Findings at Global Summit

2M ago

PremiumCompany Announcements

Neurizon Therapeutics to Present Q3 FY2025 Results and Progress on ALS Treatment

2M ago

PremiumCompany Announcements

Neurizon Therapeutics Reports Promising Results from NUZ-001 ALS Study

2M ago

See All DE:ECQ0 News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

3.83% Insiders

―

Mutual Funds

― Other Institutional Investors

96.17% Public Companies and

Individual Investors

Detailed Ownership Overview >

ECQ0 FAQ

What was Pharmaust Limited’s price range in the past 12 months?

Pharmaust Limited lowest stock price was €0.04 and its highest was €0.14 in the past 12 months.

What is Pharmaust Limited’s market cap?

Pharmaust Limited’s market cap is €42.53M.

When is Pharmaust Limited’s upcoming earnings report date?

Pharmaust Limited’s upcoming earnings report date is Aug 29, 2025 which is in 60 days.

How were Pharmaust Limited’s earnings last quarter?

Pharmaust Limited released its earnings results on Feb 17, 2025. The company reported -€0.008 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.008.

Is Pharmaust Limited overvalued?

According to Wall Street analysts Pharmaust Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharmaust Limited pay dividends?

Pharmaust Limited does not currently pay dividends.

What is Pharmaust Limited’s EPS estimate?

Pharmaust Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharmaust Limited have?

Pharmaust Limited has 492,305,760 shares outstanding.

What happened to Pharmaust Limited’s price movement after its last earnings report?

Pharmaust Limited reported an EPS of -€0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 28.571%.

Which hedge fund is a major shareholder of Pharmaust Limited?

Currently, no hedge funds are holding shares in DE:ECQ0

Pharmaust Limited Stock Smart Score

Underperform

Fundamentals

Return on Equity

-151.55%

Trailing 12-Months

Asset Growth

72.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pharmaust Limited

PharmAust Ltd operates as a drug discovery and development company in Australia, Switzerland, and internationally. It develops drug discovery intellectual property for the treatment of various cancers in humans and animals. The company offers Monepantel and Albendazole, which are in Phase II clinical trials for the treatment of cancer. It also provides medicinal and synthetic chemistry services on a contract basis to the drug discovery and pharmaceutical industries.

ECQ0 Stock 12 Month Forecast

Average Price Target

€0.25

▲(212.50%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","-1":"-€1","-0.5":"-€0.5","0.5":"€0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€0.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€0.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Aug<br/>2024","9":"Dec<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.06,0.07461538461538461,0.08923076923076922,0.10384615384615384,0.11846153846153845,0.1330769230769231,0.14769230769230768,0.16230769230769232,0.1769230769230769,0.19153846153846155,0.20615384615384616,0.22076923076923077,0.2353846153846154,{"y":0.25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.06,0.07461538461538461,0.08923076923076922,0.10384615384615384,0.11846153846153845,0.1330769230769231,0.14769230769230768,0.16230769230769232,0.1769230769230769,0.19153846153846155,0.20615384615384616,0.22076923076923077,0.2353846153846154,{"y":0.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.06,0.07461538461538461,0.08923076923076922,0.10384615384615384,0.11846153846153845,0.1330769230769231,0.14769230769230768,0.16230769230769232,0.1769230769230769,0.19153846153846155,0.20615384615384616,0.22076923076923077,0.2353846153846154,{"y":0.25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.1,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.15,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.23,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.1,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.11,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.09,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.09,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.11,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.06,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >